Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04077021 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Calibr, a division of Scripps Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04077021: Clinical Trial Phase 1 study, sponsored by Calibr, a division of Scripps Research.
NCT04077021 is a Phase 1 study that was terminated before completion, run by Calibr, a division of Scripps Research. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04077021, a Phase 1 study, was terminated before completion, sponsored by Calibr, a division of Scripps Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.
Primary Outcome
Frequency, severity, duration of treatment-emergent and treatment-related adverse events per CTCAE v5.0
Interventions
- DRUG CCW702
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2022-10-21 |
| Phase | Phase 1 |
Why NCT04077021 stopped before completion
NCT04077021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which CCW702 is the first listed.
NCT04077021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04077021 about?
NCT04077021 is a clinical study titled "First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer". CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subpar...
What is the current status of trial NCT04077021?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-07-17. Estimated completion is 2022-10-21.
What interventions are being tested in trial NCT04077021?
The interventions under investigation include: CCW702 (DRUG).
Who is sponsoring clinical trial NCT04077021?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04077021's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI